Volume 32, Issue 4 e12932
Therapeutic Hotline: Short Paper

Biologics in dermatology: What does the future hold?

Cahit Yavuz

Corresponding Author

Cahit Yavuz

Department of Dermatology, Konya Training and Research Hospital, Konya, Turkey

Correspondence

Cahit Yavuz, MD, Hacı Saban Mah, Yeni Meram Cad, No:97 Meram, Konya, Türkiye.

Email: [email protected]

Search for more papers by this author
First published: 12 April 2019
Citations: 6

Abstract

As the first dermatological biological treatment, infliximab was first used in the treatment of psoriasis in 2001. Since that time many biological agents have come into use for dermatological diseases and developments in this area are still ongoing. The most important feature of biological treatments is that the treatment must be target directed. In the light of technological developments, the concept has emerged of treatment directed to a patient-specific target.

CONFLICT OF INTEREST

Author declares no conflict of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.